NF-κB: Its Role in Colorectal Cancer

  • A. Hartley
  • H. Wei
  • L. Prabhu
  • M. Martin
  • T. LuEmail author


Colorectal cancer (CRC) is a major worldwide health problem and is the second leading cause of cancer-related deaths in the United States. Despite considerable progress in diagnosis and treatment, a high mortality rate persists, largely due to the complications associated with metastatic incidences. The pro-inflammatory transcription factor nuclear factor κB (NF-κB) is a central player in inflammatory responses and tumor progression. In CRC, constitutively activated NF-κB has been observed in the majority of patients. NF-κB significantly affects the process of tumorigenesis by promoting many aspects including tumor growth, proliferation, invasiveness, and angiogenesis. Importantly, the critical contribution of NF-κB to inflammation and tumorigenesis is due to its control of the expression of a large variety of target genes, many of which, when aberrantly expressed, help to orchestrate and promote CRC malignant potential. These NF-κB target genes include those vital to cell cycle regulation, cell proliferation, metastasis, and cell survival. Additionally, activation of NF-κB in both cancerous cells and inflammatory cells and subsequent induction of cytokines/chemokines within the tumor microenvironment also contribute to CRC cell malignancy in both autocrine and paracrine manners. These evidences implicate inhibition of NF-κB as an important approach for CRC therapy. Several recent combinatorial approaches using classical chemotherapeutics with NF-κB inhibitors seem to have resulted in very promising outcomes.


Colorectal cancer NF-κB Transcription factor 


  1. 1.
    Hawk ET, Levin B (2005) Colorectal cancer prevention. J Clin Oncol 23(2):378–391CrossRefPubMedGoogle Scholar
  2. 2.
    Hassanzadeh P (2011) Colorectal cancer and NF-κB signaling pathway. Gastroenterol Hepatol Bed Bench 4(3):127–132PubMedPubMedCentralGoogle Scholar
  3. 3.
    Vaiopoulos AG, Athanasoula K, Papavassiliou AG (2013) NF-κB in colorectal cancer. J Mol Med 91(9):1029–1037CrossRefPubMedGoogle Scholar
  4. 4.
    Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet (London, England) 357(9255):539–545CrossRefGoogle Scholar
  5. 5.
    Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860–867CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Waldner MJ, Neurath MF (2009) Colitis-associated cancer: the role of T cells in tumor development. Semin Immunopathol 31(2):249–256CrossRefPubMedGoogle Scholar
  7. 7.
    Eaden JA, Abrams KR, Mayberry JF (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48(4):526–535CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Neurath MF et al (1998) Cytokine gene transcription by NF-κB family members in patients with inflammatory bowel disease. Ann N Y Acad Sci 859:149–159CrossRefPubMedGoogle Scholar
  9. 9.
    Greten FR et al (2004) IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118(3):285–296CrossRefPubMedGoogle Scholar
  10. 10.
    Oeckinghaus A, Ghosh S (2009) The NF-κB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 1(4):a000034CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Viennois E, Chen F, Merlin D (2013) NF-κB pathway in colitis-associated cancers. Transl Gastrointest Cancer 2(1):21–29PubMedPubMedCentralGoogle Scholar
  12. 12.
    Sun SC (2011) Non-canonical NF-κB signaling pathway. Cell Res 21(1):71–85CrossRefGoogle Scholar
  13. 13.
    Wei H et al (2013) PRMT5 dimethylates R30 of the p65 subunit to activate NF-κB. Proc Natl Acad Sci U S A 110(33):13516–13521CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Lu T et al (2010) Regulation of NF-κB by NSD1/FBXL11-dependent reversible lysine methylation of p65. Proc Natl Acad Sci U S A 107(1):46–51CrossRefPubMedGoogle Scholar
  15. 15.
    Vermeulen K, Van Bockstaele DR, Berneman ZN (2003) The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36(3):131–149CrossRefPubMedGoogle Scholar
  16. 16.
    Hall M, Peters G (1996) Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 68:67–108CrossRefPubMedGoogle Scholar
  17. 17.
    Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G (1993) Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 7(5):812–821CrossRefPubMedGoogle Scholar
  18. 18.
    Pagano M, Theodoras AM, Tam SW, Draetta GF (1994) Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts. Genes Dev 8(14):1627–1639CrossRefPubMedGoogle Scholar
  19. 19.
    Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr (1999) NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19(8):5785–5799CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Li Y, Wei J, Xu C, Zhao Z, You T (2014) Prognostic significance of cyclin D1 expression in colorectal cancer: a meta-analysis of observational studies. PLoS One 9(4):e94508CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Albanese C et al (1995) Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem 270(40):23589–23597CrossRefPubMedGoogle Scholar
  22. 22.
    Tetsu O, McCormick F (1999) β-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398(6726):422–426CrossRefGoogle Scholar
  23. 23.
    Hinz M et al (1999) NF-κB function in growth control: regulation of cyclin D1 expression and G(0)/G(1)-to-S-phase transition. Mol Cell Biol 19(4):2690–2698CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Matsumura I et al (1999) Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells. EMBO J 18(5):1367–1377CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Leslie K et al (2006) Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. Cancer Res 66(5):2544–2552CrossRefPubMedGoogle Scholar
  26. 26.
    Karin M, Cao Y, Greten FR, Li ZW (2002) NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2(4):301–310CrossRefGoogle Scholar
  27. 27.
    Bond M, Fabunmi RP, Baker AH, Newby AC (1998) Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-κB. FEBS Lett 435(1):29–34CrossRefPubMedGoogle Scholar
  28. 28.
    Gupta SC, Kim JH, Prasad S, Aggarwal BB (2010) Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 29(3):405–434CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Su CC, Chen GW, Lin JG, Wu LT, Chung JG (2006) Curcumin inhibits cell migration of human colon cancer colo 205 cells through the inhibition of nuclear factor κB/p65 and down-regulates cyclooxygenase-2 and matrix metalloproteinase-2 expressions. Anticancer Res 26(2a):1281–1288PubMedGoogle Scholar
  30. 30.
    Choo MK, Sakurai H, Kim DH, Saiki I (2008) A ginseng saponin metabolite suppresses tumor necrosis factor-α-promoted metastasis by suppressing nuclear factor-κB signaling in murine colon cancer cells. Oncol Rep 19(3):595–600PubMedGoogle Scholar
  31. 31.
    Kulbe H, Hagemann T, Szlosarek PW, Balkwill FR, Wilson JL (2005) The inflammatory cytokine tumor necrosis factor-α regulates chemokine receptor expression on ovarian cancer cells. Cancer Res 65(22):10355–10362CrossRefPubMedGoogle Scholar
  32. 32.
    Killeen SD, Wang JH, Andrews EJ, Redmond HP (2009) Bacterial endotoxin enhances colorectal cancer cell adhesion and invasion through TLR-4 and NF-κB-dependent activation of the urokinase plasminogen activator system. Br J Cancer 100(10):1589–1602CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Abdullah M et al (2013) Expression of NF-κB and COX2 in colorectal cancer among native Indonesians: the role of inflammation in colorectal carcinogenesis. Acta Med Indones 45(3):187–192PubMedGoogle Scholar
  34. 34.
    Huber MA et al (2004) NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 114(4):569–581CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Bachelder RE, Yoon SO, Franci C, de Herreros AG, Mercurio AM (2005) Glycogen synthase kinase-3 is an endogenous inhibitor of snail transcription: implications for the epithelial-mesenchymal transition. J Cell Biol 168(1):29–33CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Lockyer JM, Colladay JS, Alperin-Lea WL, Hammond T, Buda AJ (1998) Inhibition of nuclear factor-κB-mediated adhesion molecule expression in human endothelial cells. Circ Res 82(3):314–320CrossRefPubMedGoogle Scholar
  37. 37.
    Wu Y, Zhou BP (2010) TNF-α/NF-κB/snail pathway in cancer cell migration and invasion. Br J Cancer 102(4):639–644CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Bendardaf R et al (2008) VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival. Anticancer Res 28(6b):3865–3870PubMedGoogle Scholar
  39. 39.
    Di Caro G et al (2016) Circulating inflammatory mediators as potential prognostic markers of human colorectal cancer. PLoS One 11(2):e0148186CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    McMahon G (2000) VEGF receptor signaling in tumor angiogenesis. Oncologist 5(Suppl 1):3–10CrossRefPubMedGoogle Scholar
  41. 41.
    Heidemann J et al (2003) Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J Biol Chem 278(10):8508–8515CrossRefPubMedGoogle Scholar
  42. 42.
    Martin D, Galisteo R, Gutkind JS (2009) CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NF-κB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem 284(10):6038–6042CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Spano JP et al (2005) Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann Oncol 16(2):189–194CrossRefPubMedGoogle Scholar
  44. 44.
    Piazzi G, Paterini P, Ceccarelli C, Pantaleo MA, Biasco G (2006) Molecular determination of epidermal growth factor receptor in normal and neoplastic colorectal mucosa. Br J Cancer 95(11):1525–1528CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Shostak K, Chariot A (2015) EGFR and NF-κB: partners in cancer. Trends Mol Med 21(6):385–393CrossRefPubMedGoogle Scholar
  46. 46.
    Shao J et al (2000) Overexpression of the wild-type p53 gene inhibits NF-κB activity and synergizes with aspirin to induce apoptosis in human colon cancer cells. Oncogene 19(6):726–736CrossRefPubMedGoogle Scholar
  47. 47.
    Lin A, Karin M (2003) NF-κB in cancer: a marked target. Semin Cancer Biol 13(2):107–114CrossRefPubMedGoogle Scholar
  48. 48.
    Cusack JC Jr, Liu R, Baldwin AS Jr (2000) Inducible chemoresistance to 7-ethyl-10-[4-1-(piperidino)-1-piperidino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-κB activation. Cancer Res 60(9):2323–2330PubMedGoogle Scholar
  49. 49.
    Luo Y et al (2014) Apoptotic effect of genistein on human colon cancer cells via inhibiting the nuclear factor-κB (NF-κB) pathway. Tumour Biol 35(11):11483–11488CrossRefPubMedGoogle Scholar
  50. 50.
    Zhang XA, Zhang S, Yin Q, Zhang J (2015) Quercetin induces human colon cancer cells apoptosis by inhibiting the nuclear factor-κB pathway. Pharmacogn Mag 11(42):404–409CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Chen F et al (2003) Phosphorylation of PPARγ via active ERK1/2 leads to its physical association with p65 and inhibition of NF-κB. J Cell Biochem 90(4):732–744CrossRefPubMedGoogle Scholar
  52. 52.
    Kimura M et al (2003) TNF combined with IFN-α accelerates NF-κB-mediated apoptosis through enhancement of Fas expression in colon cancer cells. Cell Death Differ 10(6):718–728CrossRefPubMedGoogle Scholar
  53. 53.
    Liu F et al (2012) NF-κB directly regulates Fas transcription to modulate Fas-mediated apoptosis and tumor suppression. J Biol Chem 287(30):25530–25540CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Anitha A, Deepa N, Chennazhi KP, Lakshmanan V-K, Jayakumar R (2014) Combinatorial anticancer effects of curcumin and 5-fluorouracil loaded thiolated chitosan nanoparticles towards colon cancer treatment. Biochim Biophys Acta Gen Subj 1840(9):2730–2743CrossRefGoogle Scholar
  55. 55.
    Adams J (2002) Proteasome inhibition: a novel approach to cancer therapy. Trends Mol Med 8(4 Suppl):S49–S54CrossRefPubMedGoogle Scholar
  56. 56.
    Majumdar S, Aggarwal BB (2001) Methotrexate suppresses NF-κB activation through inhibition of IκBα phosphorylation and degradation. J Immunol (Baltimore, Md: 1950) 167(5):2911–2920CrossRefGoogle Scholar
  57. 57.
    Weber CK, Liptay S, Wirth T, Adler G, Schmid RM (2000) Suppression of NF-κB activity by sulfasalazine is mediated by direct inhibition of IκB kinases α and β. Gastroenterology 119(5):1209–1218CrossRefPubMedGoogle Scholar
  58. 58.
    Chang CK, Llanes S, Schumer W (1997) Effect of dexamethasone on NF-κB activation, tumor necrosis factor formation, and glucose dyshomeostasis in septic rats. J Surg Res 72(2):141–145CrossRefPubMedGoogle Scholar
  59. 59.
    Yamamoto Y, Gaynor RB Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Invest 107(2):135–142CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Sakamoto K et al (2009) Constitutive NF-κB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Clin Cancer Res 15(7):2248–2258CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd 2017

Authors and Affiliations

  • A. Hartley
    • 1
  • H. Wei
    • 1
  • L. Prabhu
    • 1
  • M. Martin
    • 1
  • T. Lu
    • 1
    • 2
    • 3
    Email author
  1. 1.Department of Pharmacology and ToxicologyIndiana University School of MedicineIndianapolisUSA
  2. 2.Department of Biochemistry and Molecular BiologyIndiana University School of MedicineIndianapolisUSA
  3. 3.Department of Medical and Molecular GeneticsIndiana University School of MedicineIndianapolisUSA

Personalised recommendations